DK0862634T4 - Farmaceutisk præparat mod papillomavirustumorer og -infektioner - Google Patents

Farmaceutisk præparat mod papillomavirustumorer og -infektioner

Info

Publication number
DK0862634T4
DK0862634T4 DK97935646T DK97935646T DK0862634T4 DK 0862634 T4 DK0862634 T4 DK 0862634T4 DK 97935646 T DK97935646 T DK 97935646T DK 97935646 T DK97935646 T DK 97935646T DK 0862634 T4 DK0862634 T4 DK 0862634T4
Authority
DK
Denmark
Prior art keywords
infections
pharmaceutical preparation
polypeptide
iii
papillomavirus
Prior art date
Application number
DK97935646T
Other languages
Danish (da)
English (en)
Other versions
DK0862634T3 (da
Inventor
Jean-Marc Balloul
Nadine Bizouarne
Marie-Paule Kieny
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9494633&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0862634(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Transgene Sa filed Critical Transgene Sa
Application granted granted Critical
Publication of DK0862634T3 publication Critical patent/DK0862634T3/da
Publication of DK0862634T4 publication Critical patent/DK0862634T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
DK97935646T 1996-07-30 1997-07-29 Farmaceutisk præparat mod papillomavirustumorer og -infektioner DK0862634T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9609584A FR2751879B1 (fr) 1996-07-30 1996-07-30 Composition pharmaceutique contre les tumeurs et infections a papillomavirus
PCT/FR1997/001412 WO1998004705A1 (fr) 1996-07-30 1997-07-29 Composition pharmaceutique contre les tumeurs et infections a papillomavirus

Publications (2)

Publication Number Publication Date
DK0862634T3 DK0862634T3 (da) 2002-01-21
DK0862634T4 true DK0862634T4 (da) 2006-05-08

Family

ID=9494633

Family Applications (2)

Application Number Title Priority Date Filing Date
DK97935646T DK0862634T4 (da) 1996-07-30 1997-07-29 Farmaceutisk præparat mod papillomavirustumorer og -infektioner
DK01109013T DK1149910T3 (da) 1996-07-30 1997-07-29 Farmaceutisk præparat til behandling af papillomavirustumorer og -infektion

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK01109013T DK1149910T3 (da) 1996-07-30 1997-07-29 Farmaceutisk præparat til behandling af papillomavirustumorer og -infektion

Country Status (12)

Country Link
EP (2) EP0862634B2 (ja)
JP (2) JP4070815B2 (ja)
AT (2) ATE205881T1 (ja)
AU (1) AU736720B2 (ja)
CA (1) CA2234263C (ja)
DE (2) DE69728914T2 (ja)
DK (2) DK0862634T4 (ja)
ES (2) ES2163795T5 (ja)
FR (1) FR2751879B1 (ja)
HK (1) HK1043809B (ja)
PT (2) PT1149910E (ja)
WO (1) WO1998004705A1 (ja)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7494658B2 (en) 1998-02-20 2009-02-24 Medigene Ag Papilloma virus truncated L1 protein and fusion protein constructs
US7182947B2 (en) 1998-02-20 2007-02-27 Medigene Ag Papillomavirus truncated L1 protein and fusion protein constructs
CA2229955C (en) 1998-02-20 2003-12-09 Medigene Gmbh Papilloma virus capsomere vaccine formulations and methods of use
US20020039584A1 (en) 1998-02-20 2002-04-04 Medigene Ag Papilloma virus capsomere vaccine formulations and methods of use
US6926897B1 (en) 1998-03-24 2005-08-09 Medigene Aktiengesellschaft Medicament for the avoidance or treatment of papillomavirus-specific tumour
WO2000000217A1 (fr) * 1998-06-26 2000-01-06 Aventis Pasteur Immunisation a ciblage mucosal
HUE037866T2 (hu) 2006-06-20 2018-09-28 Transgene Sa Eljárás poxvírusok és poxvírus-készítmények elõállítására
EP2382474B1 (en) 2009-01-20 2015-03-04 Transgene SA Soluble icam-1 as biomarker for prediction of therapeutic response
SG2014014021A (en) 2009-03-24 2014-07-30 Transgene Sa Biomarker for monitoring patients
BRPI1010512A2 (pt) 2009-04-17 2016-03-15 Transgène S A "método ex vivo para avaliar a eficácia de um tratamento envolvendo a administração de uma composição imunogênica a um paciente, e, uso de níveis de linfócitos t ativados (cd3 + cd69+) como um biomarcador"
US8445270B2 (en) 2009-05-12 2013-05-21 Transgene S.A. Immortalized avian cell lines and use thereof
AU2010270313B2 (en) 2009-07-10 2014-05-22 Transgene Sa Biomarker for selecting patients and related methods
WO2011009613A1 (en) 2009-07-21 2011-01-27 Transgene Sa Enzymatic composition for the digestion of chicken embryos
TWI690322B (zh) 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用
AU2015357225B2 (en) 2014-12-01 2020-04-09 Transgene Sa Stable liquid vaccinia virus formulations
FR3042121A1 (fr) * 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
US11306292B2 (en) 2017-05-15 2022-04-19 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
EP3624845A1 (en) 2017-05-15 2020-03-25 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
CA3111273C (en) 2018-09-06 2024-03-26 Bavarian Nordic A/S Storage improved poxvirus compositions
IL296250A (en) 2020-03-12 2022-11-01 Bavarian Nordic As The compounds that improve the stability of the smallpox virus

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2643817B1 (fr) * 1989-03-06 1993-12-17 Transgene Sa Composition pharmaceutique, utile a titre preventif ou curatif contre les tumeurs induites par les papillomavirus
IE910909A1 (en) † 1990-03-20 1991-09-25 Behringwerke Ag Seroreactive epitopes of human Papillomavirus (HPV) 16¹proteins
GB9113809D0 (en) * 1991-06-26 1991-08-14 Cancer Res Campaign Tech Papillomavirus l2 protein
DK1359156T3 (da) * 1991-07-19 2007-04-10 Univ Queensland Vaccine mod humanpapillomavirus
US5618536A (en) * 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
GB9306731D0 (en) * 1993-03-31 1993-05-26 Cancer Res Campaign Tech Vaccines
IL113817A (en) * 1994-06-30 2001-03-19 Merck & Co Inc Polynucleotide for vaccination against the umbilical cord virus
WO1996011279A2 (en) * 1994-10-03 1996-04-18 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system
GB9505784D0 (en) * 1995-03-22 1995-05-10 Lynxvale Ltd Anti-tumour treatment
FR2749323B1 (fr) * 1996-06-04 1998-07-10 Pasteur Merieux Serums Vacc Pseudo-particules virales utiles en tant que vecteur de delivrance d'acide nucleique

Also Published As

Publication number Publication date
DE69728914T2 (de) 2005-04-07
AU3855297A (en) 1998-02-20
ES2163795T5 (es) 2006-07-16
DE69706825T3 (de) 2006-08-24
EP0862634B1 (fr) 2001-09-19
DE69706825T2 (de) 2002-05-02
PT862634E (pt) 2002-03-28
PT1149910E (pt) 2004-09-30
DE69706825D1 (de) 2001-10-25
ATE265535T1 (de) 2004-05-15
FR2751879B1 (fr) 1998-10-30
AU736720B2 (en) 2001-08-02
ES2163795T3 (es) 2002-02-01
HK1043809A1 (en) 2002-09-27
EP1149910A1 (fr) 2001-10-31
JP4070815B2 (ja) 2008-04-02
JP4198735B2 (ja) 2008-12-17
DK1149910T3 (da) 2004-08-02
FR2751879A1 (fr) 1998-02-06
EP0862634A1 (fr) 1998-09-09
CA2234263A1 (fr) 1998-02-05
ATE205881T1 (de) 2001-10-15
JP2000500662A (ja) 2000-01-25
DE69728914D1 (de) 2004-06-03
JP2007254474A (ja) 2007-10-04
CA2234263C (fr) 2009-10-13
WO1998004705A1 (fr) 1998-02-05
DK0862634T3 (da) 2002-01-21
HK1043809B (zh) 2004-12-03
EP0862634B2 (fr) 2006-03-01
EP1149910B1 (fr) 2004-04-28
ES2215805T3 (es) 2004-10-16

Similar Documents

Publication Publication Date Title
DK0862634T4 (da) Farmaceutisk præparat mod papillomavirustumorer og -infektioner
UA39158C2 (uk) Похідні n4-оксикарбоніл-5'-дезокси-5-фторцитидину та фармацевтичний препарат на їх основі
DE69729786D1 (de) Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen
NO924172D0 (no) Substituerte bifenylpyridoner
FI891361A0 (fi) Menetelmä farmaseuttisesti vaikuttavien aryylihydratsonien valmistamiseksi
EA200200479A1 (ru) Новые олигосахариды, их получение и содержащие их фармацевтические композиции
AU589939B2 (en) Medical composition for injection containing a spergualin as active ingredient and process for preparing the same
FI923347A0 (fi) Blodfaktorer producerade med rekombinant-dna-teknik och foerfarande foer expression av naemnda blodfaktorer samt i naemnda foerfarande anvaenda rekombinanta kokoppvirus.
CS156792A3 (en) Substituted diaminophthalimides and compounds analogous thereto
KR0180256B1 (en) Bpc peptides, their preparation and use
MD502G2 (ro) Derivaţi noi ai adenozinei, procedee de preparare a lor, compoziţii farmaceutice ce le conţin
CA2263846A1 (en) Novel pyranoside derivatives
MY101169A (en) Novel phenylureas
EP1074264A4 (en) NEOVASCULARIZATION INHIBITORS
AU6722498A (en) Disubstituted biphenyloxazolines
ZA953584B (en) Novel active peptide and its preparation
DE69614552D1 (de) MODIFIZIERTE ALPHA-D-GLCP-(1,2)-ALPHA-D-Glcp-(1,3)-ALPHA-D-Glcp-ANALOGE
RU94019328A (ru) α- ГЕТЕРОАРИЛОКСИМЕТИЛКЕТОНЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ИНГИБИРУЮЩАЯ ИНТЕРЛЕЙКИН-1 - β -ПРОТЕАЗУ
IT8619383A0 (it) Nuovi composti ad attivita'colinergica, procedimento per laloro preparazione e relative composizioni farmaceutiche.
IT8619384A0 (it) Composti ad attivita'epatoprotettrice e mucolitica, procedimento per la loro preparazione e composizioni farmaceutiche relative.
IT8719352A0 (it) Nuovi composti ad attivita'colinergica, procedimento per laloro preparazione e relative composizioni farmaceutiche.
CA2234611A1 (en) New phenylamidine derivatives, processes for preparing them and their use as pharmaceutical compositions